...
首页> 外文期刊>International journal of clinical pharmacology and therapeutics >Lines of therapy with biological drugs in dermatology, gastroenterology, and rheumatology practices in Germany
【24h】

Lines of therapy with biological drugs in dermatology, gastroenterology, and rheumatology practices in Germany

机译:德国皮肤病学中的生物药物,胃肠病学和风湿病学实践的疗法疗法

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Objective: The goal of the present study was to investigate lines of therapy with biological drugs in patients followed in dermatology. gastroenterology, and rheumatology practices in Germany. Materials and methods: The study included patients aged 18 years or over who had received a biological therapy in dermatology, gastroenterology, or rheumatology practices in Germany in 2017 (index date). The primary outcome of the study was the prevalence of different lines of therapy (first-, second-, third-, and at least fourth-line therapies) by type of practice, age. and gender. The second outcome was the association between basic characteristics (type of practice, age, and gender) and lines of therapy with biological drugs. Results: The present study included 27.816 individuals. The mean age (SD) at index date was 50.7 years (15.4 years). Biological drugs were prescribed as first-line therapies in 60% of patients (dermatology 73%, gastroenterology 61%, and rheumatology 56%). The prevalence of first-line therapies ranged from 57% in individuals aged 41 - 50 years to 65% in those aged 18 - 30 years. Furthermore, 56% of women and 61% of men were prescribed biological drugs as first-line therapies. Finally, the likelihood of being prescribed biological drugs as second-, third-, or at least fourth-line therapies was significantly associated with being followed in a rheumatology or gastroenterology practice, older age, and female gender. Conclusion: Biological drugs were prescribed as first-line therapies in most cases. The type of practice as well as the patient's age and gender had a significant impact on lines of therapy with biological drugs.
机译:目的:目前研究的目的是调查皮肤科患者的生物药物治疗疗法。德国胃肠学和风湿病学实践。材料和方法:该研究包括2017年德国皮肤病学,胃肠学或风湿病学实践的18岁或以上的患者(指数日期)。该研究的主要结果是通过练习类型,年龄的不同治疗方法(第一,第二,,第三和至少第四线疗法)的患病率。和性别。第二种结果是基本特征(实践类型,年龄和性别的类型)和生物药物的疗法之间的关联。结果:本研究包括27.816人。指数日期的平均年龄(SD)为50.7岁(15.4岁)。在60%的患者(皮肤病学73%,胃肠学61%和风湿病学56%)中,生物药物被规定为一线疗法。第一线疗法的患病率从41-50岁的人中的57%达到65%,达到18至30岁。此外,56%的女性和61%的男性被规定为一线疗法。最后,作为第二,第三 - ,第三线疗法被规定的生物药物的可能性与随后的风湿病或胃肠学实践,年龄较大的年龄和女性性别显着相关。结论:在大多数情况下,生物药物被规定为一线疗法。练习类型以及患者的年龄和性别对生物药物的治疗疗法产生重大影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号